CMND net incomeFY2025-$3.86M
CMND net income was -$3.86M for fiscal 2025 (ended Oct 31, 2025), compared with -$5.25M in fiscal 2024.
Clearmind Medicine Inc. (CMND) financials
For fiscal 2025 (ended Oct 31, 2025), Clearmind Medicine Inc. reported -$3.86M of net income.
- Net income, FY2025
- -$3.86M
- EPS, diluted, FY2025
- -$30.35
- Cash
- $3.92M
- Market cap
- $2.8M
FY2021FY2025
FY2021FY2022
CMND revenue and earnings growth
CMND EPSFY2025-$30.35
CMND diluted EPS was -$30.35 for fiscal 2025 (ended Oct 31, 2025).
Income statement
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 |
|---|---|---|---|---|---|
| Research and development | $2.06M | $1.38M | $1.54M | $3.08M | $473.7K |
| Selling, general and admin | $3.61M | $4.36M | $4.76M | $3.17M | $2.22M |
| Interest expense | $3.9K | $5.4K | - | - | - |
| Pre-tax income | -$3.79M | -$4.88M | -$8.60M | -$6.87M | -$2.73M |
| Income tax | $70.4K | $378.0K | $17.4K | $29.9K | - |
| Net income | -$3.86M | -$5.25M | -$8.62M | -$6.89M | -$2.73M |
| EPS, basic | -$30.35 | -$67.80 | -$1703.04 | -$6364.40 | -$3526.40 |
| EPS, diluted | -$30.35 | -$67.80 | -$1703.04 | -$6364.40 | -$3526.40 |
| Diluted shares | 127,093 | 77,503 | 5,062 | 1,083.375 | 772.775 |
Balance sheet
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $3.92M | $6.57M | $5.43M | $128.8K | $3.37M |
| Current assets | $5.95M | $7.09M | $5.79M | $434.7K | - |
| Total assets | $6.08M | $7.26M | $5.95M | $826.4K | - |
| Current liabilities | $4.89M | $4.13M | $4.97M | - | - |
| Total liabilities | $4.89M | $4.15M | $4.97M | $1.93M | - |
| Shareholders' equity | $1.19M | $3.11M | $983.5K | -$1.11M | $3.52M |
Cash flow
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.73M | -$4.86M | -$6.30M | -$3.72M | -$2.08M |
| Capital expenditures | - | - | - | $5.6K | $17.0K |
| Free cash flow | - | - | - | -$3.73M | -$2.09M |
| Investing cash flow | -$542.0K | -$238.1K | -$26.2K | -$5.6K | -$184.0K |
| Financing cash flow | $2.62M | $6.25M | $11.66M | $511.7K | $5.39M |
| Stock-based compensation | $805.9K | $998.9K | $834.8K | $1.21M | $619.9K |
Key ratios
Source: XBRL data Clearmind Medicine Inc. files with the SEC, latest filing dated Jan 20, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-40, first reported Jan 20, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
CMND peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CMND | - | - | -$3.86M | - | $2.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
CMND FAQ
5 questionsIs CMND profitable?
No. Clearmind Medicine Inc. reported a net loss of $3.86M for fiscal 2025 (ended Oct 31, 2025).How much cash and debt does CMND have?
Clearmind Medicine Inc. reported $3.92M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CMND earnings per share?
Diluted earnings per share were -$30.35 for fiscal 2025 (ended Oct 31, 2025), from SEC filings, restated for any stock split those filings show.When did CMND last report financial results?
The latest statements here come from Clearmind Medicine Inc.'s 20-F filed on Jan 20, 2026, covering the period ended Oct 31, 2025.Where does this CMND financial data come from?
Quantisnow builds these statements from the structured XBRL data Clearmind Medicine Inc. files with the SEC. It is provided for information only and is not investment advice.